Alnylam Pharmaceuticals, Inc. $ALNY Shares Bought by Victory Capital Management Inc.

Victory Capital Management Inc. grew its position in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) by 15.4% during the third quarter, according to its most recent Form 13F filing with the SEC. The firm owned 180,349 shares of the biopharmaceutical company’s stock after purchasing an additional 24,055 shares during the period. Victory Capital Management Inc.’s holdings in Alnylam Pharmaceuticals were worth $82,239,000 at the end of the most recent quarter.

Other institutional investors and hedge funds have also recently modified their holdings of the company. CI Investments Inc. increased its holdings in Alnylam Pharmaceuticals by 75.6% in the 3rd quarter. CI Investments Inc. now owns 7,224 shares of the biopharmaceutical company’s stock worth $3,294,000 after buying an additional 3,109 shares during the period. Focus Partners Advisor Solutions LLC boosted its holdings in shares of Alnylam Pharmaceuticals by 533.0% in the 3rd quarter. Focus Partners Advisor Solutions LLC now owns 5,127 shares of the biopharmaceutical company’s stock valued at $2,282,000 after acquiring an additional 4,317 shares during the last quarter. Elo Mutual Pension Insurance Co increased its stake in shares of Alnylam Pharmaceuticals by 26.5% in the third quarter. Elo Mutual Pension Insurance Co now owns 17,865 shares of the biopharmaceutical company’s stock worth $8,146,000 after acquiring an additional 3,738 shares during the period. Quantbot Technologies LP purchased a new position in shares of Alnylam Pharmaceuticals during the third quarter worth $536,000. Finally, Aster Capital Management DIFC Ltd acquired a new position in Alnylam Pharmaceuticals during the third quarter valued at $36,000. Institutional investors and hedge funds own 92.97% of the company’s stock.

Insider Transactions at Alnylam Pharmaceuticals

In related news, EVP Pushkal Garg sold 1,775 shares of Alnylam Pharmaceuticals stock in a transaction that occurred on Tuesday, March 3rd. The stock was sold at an average price of $319.74, for a total transaction of $567,538.50. Following the transaction, the executive vice president owned 23,406 shares in the company, valued at approximately $7,483,834.44. This trade represents a 7.05% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which can be accessed through this link. Also, EVP Tolga Tanguler sold 1,598 shares of the company’s stock in a transaction on Monday, March 2nd. The shares were sold at an average price of $327.65, for a total value of $523,584.70. Following the completion of the sale, the executive vice president owned 36,606 shares of the company’s stock, valued at approximately $11,993,955.90. The trade was a 4.18% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. In the last 90 days, insiders have sold 53,923 shares of company stock valued at $18,072,087. 1.50% of the stock is currently owned by company insiders.

Alnylam Pharmaceuticals Price Performance

Shares of NASDAQ ALNY opened at $320.51 on Friday. The firm has a 50-day simple moving average of $353.84 and a 200-day simple moving average of $415.74. The company has a quick ratio of 2.71, a current ratio of 2.76 and a debt-to-equity ratio of 1.28. The stock has a market capitalization of $42.51 billion, a price-to-earnings ratio of 187.43 and a beta of 0.36. Alnylam Pharmaceuticals, Inc. has a 52 week low of $205.87 and a 52 week high of $495.55.

Alnylam Pharmaceuticals (NASDAQ:ALNY) last released its quarterly earnings data on Thursday, February 12th. The biopharmaceutical company reported $1.25 EPS for the quarter, missing analysts’ consensus estimates of $1.43 by ($0.18). Alnylam Pharmaceuticals had a net margin of 6.43% and a return on equity of 69.02%. The business had revenue of $1.10 billion during the quarter, compared to analyst estimates of $1.16 billion. During the same quarter in the previous year, the company posted ($0.65) EPS. The firm’s revenue was up 84.9% on a year-over-year basis. On average, equities analysts predict that Alnylam Pharmaceuticals, Inc. will post -1.7 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

ALNY has been the topic of several analyst reports. Bank of America reaffirmed a “buy” rating on shares of Alnylam Pharmaceuticals in a research report on Thursday, February 12th. Wall Street Zen cut Alnylam Pharmaceuticals from a “strong-buy” rating to a “buy” rating in a research report on Saturday, February 14th. HC Wainwright restated a “buy” rating and issued a $510.00 price objective on shares of Alnylam Pharmaceuticals in a research report on Wednesday, February 18th. Weiss Ratings raised shares of Alnylam Pharmaceuticals from a “sell (d-)” rating to a “hold (c-)” rating in a report on Thursday, January 15th. Finally, Chardan Capital decreased their target price on shares of Alnylam Pharmaceuticals from $475.00 to $425.00 and set a “buy” rating for the company in a research note on Friday, February 13th. One equities research analyst has rated the stock with a Strong Buy rating, twenty-two have assigned a Buy rating and five have issued a Hold rating to the stock. According to MarketBeat, the company has an average rating of “Moderate Buy” and an average target price of $477.96.

Key Headlines Impacting Alnylam Pharmaceuticals

Here are the key news stories impacting Alnylam Pharmaceuticals this week:

• Positive Sentiment: Alnylam signed a research collaboration with Tenaya Therapeutics to identify cardiovascular genetic targets; deal includes up to $10M upfront plus up to $1.13B in milestones — expands Alnylam’s RNAi pipeline into a large new therapeutic area and creates material long?term upside. Tenaya deal
• Positive Sentiment: Coverage highlights a Canadian reimbursement for AMVUTTRA and other reimbursement wins/trial progress that improve near?term revenue visibility for Alnylam’s marketed RNAi drugs. These commercial developments reduce execution risk and support upside to current valuation. Canada AMVUTTRA reimbursement
• Positive Sentiment: Analyst and industry commentary notes favorable trial progress and orphan?drug market tailwinds that underpin medium?to?longer term demand for Alnylam’s rare?disease franchise. Reimbursement & trial progress
• Neutral Sentiment: Tenaya’s stock pulled back after-hours following the deal-driven rally — notable for market reaction to the collaboration but not directly material to Alnylam’s fundamentals. TNYA market reaction
• Neutral Sentiment: Short?interest figures in recent reports show implausible “0 shares / 0 days” values — likely a reporting glitch and not a real repositioning signal for ALNY holders.
• Negative Sentiment: Clustered insider selling: CEO Yvonne Greenstreet and several EVPs disclosed multi?thousand?share sales (total proceeds in the low?millions). While insiders still hold large positions, the concentrated, contemporaneous sales can create negative sentiment and short?term downward pressure on the stock. CEO SEC filing

Alnylam Pharmaceuticals Company Profile

Alnylam Pharmaceuticals, Inc (NASDAQ: ALNY) is a biopharmaceutical company focused on the discovery, development and commercialization of RNA interference (RNAi) therapeutics. Founded to translate the scientific discovery of RNAi into new medicines, Alnylam applies small interfering RNA (siRNA) technology to silence disease-causing genes. The company develops therapies designed to provide durable disease modification by targeting underlying genetic drivers across a range of rare and more prevalent conditions.

Alnylam has advanced multiple siRNA-based products into commercialization, initially using lipid nanoparticle delivery and more recently employing GalNAc-conjugate chemistry to enable targeted delivery to the liver with subcutaneous dosing.